Recently, we reported the association between sarcopenia and nonalcoholic fatty liver disease (NAFLD) in *Journal of Obesity & Metabolic Syndrome*.[@ref1] In our study, younger age seemed to strongly impact the association between sarcopenia and NAFLD. However, this finding is not consistent, as shown in the findings by Kim et al.[@ref2] that older adults (≥45 years) had a stronger association between sarcopenia and NAFLD.

The mechanism through which age is an effect modifier is not clear, but analyzing the clinical characteristics according to age, as suggested in the letter, would be helpful in estimating the components. Thus, we compared several body compositions and metabolic and inflammatory parameters according to age group.

In all subjects, with or without sarcopenia, waist circumference and visceral adipose tissue area increased while skeletal muscle mass decreased with age (data not shown). Similarly, blood pressure and blood glucose level increased with age. On the other hand, triglycerides, high-density lipoprotein (HDL)-cholesterol, and alanine aminotransferase levels were not significantly different among age groups. Also, high-sensitivity C-reactive protein (hs-CRP) level as an inflammatory marker was not significantly different according to age group (data not shown).

However, in subjects with sarcopenia, younger subjects were more likely to be male and had higher body mass index, waist circumference, and skeletal muscle mass ([Table 1](#T1){ref-type="table"}). They also showed higher uric acid, triglyceride, and total and low-density lipoprotein (LDL)-cholesterol level and lower HDL-cholesterol level. Again, hs-CRP level showed no difference ([Table 1](#T1){ref-type="table"}). Male sex, obesity/abdominal obesity, and worse metabolic profiles shown in blood tests can be related to insulin resistance, an important risk factor for NAFLD. Even though sex and visceral adiposity were adjusted in the subgroup analysis of our previous study, the residual effect of insulin resistance might have influenced the association between sarcopenia and NALFD. In our study population, most young subjects with sarcopenia had sarcopenic obesity. Only two people in the tertile 1 (19--49 years) age group were non-obese and sarcopenic. Therefore, we were not able to compare metabolic profiles between young sarcopenic subjects with or without obesity.

A previous study by Srikanthan et al.[@ref3] reported that sarcopenia was more strongly associated with insulin resistance in a younger group (\<60 years). In that study, not only sarcopenic obesity, but also sarcopenia without obesity was significantly associated with insulin resistance. However, data from Korea National Health and Nutrition Examination Survey 2009--2010 showed no age-related effect modification between sarcopenia and insulin resistance.[@ref4] In a study reporting decrease in skeletal muscle mass as an independent risk factor for incident NAFLD, the subjects in a younger age subgroup (\<45 years) did not show such an association.[@ref5] However, in non-obese subjects, decreased muscle mass over time was a risk factor for NAFLD even in a younger age group.[@ref5] As such, findings of the association between sarcopenia and insulin resistance or NALFD vary depending on the study. The discrepancy between study results could be due to differences in study design and population characteristics.

In our study, an increase in insulin resistance at a younger age could be explained in part by obesity/abdominal obesity in this group. Unfortunately, detailed analysis of the association between sarcopenia with or without obesity and NAFLD was difficult to perform using the data. Differences in etiology of sarcopenia, changes in muscle fiber type distribution, and intramyocellular lipid accumulation have been suggested as possible mechanisms of age-related differences in the association between sarcopenia and insulin resistance.[@ref3] Further studies are needed to determine whether there is an effect modification by age and whether these factors cause differences in insulin resistance.

The effect of chronic inflammation in the association between sarcopenia and NAFLD did not seem to be major. However, chronic inflammation is regarded as an important mediator of insulin resistance,[@ref6] so future studies should evaluate it as a potential factor for mediating the association between sarcopenia and NAFLD. We are grateful for the opportunity to look deeper into our data based on this response letter.
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###### 

Clinical characteristics of subjects with sarcopenia according to age

  Variable                            T1 (19--49 yr, n= 82)                                                       T2 (50--57 yr, n= 65)                       T3 (58--87 yr, n= 168)   Total (n= 315)   *P*
  ----------------------------------- --------------------------------------------------------------------------- ------------------------------------------- ------------------------ ---------------- ---------------------------------------
  Age (yr)                            42.1±4.8[\*](#t1f2){ref-type="table-fn"},[†](#t1f2){ref-type="table-fn"}    53.0±2.3[‡](#t1f2){ref-type="table-fn"}     65.9±6.0                 57.1±11.4        \<0.001
  Male (n, %)                         69 (84.1)                                                                   48 (73.8)                                   113 (67.3)               230 (73)         0.018[\*](#t1f2){ref-type="table-fn"}
  Systolic blood pressure (mmHg)      123.0±13.1                                                                  122.2±14.1                                  125.4±14.7               124.1±14.2       0.228
  Diastolic blood pressure (mmHg)     0.8±10.7[†](#t1f2){ref-type="table-fn"}                                     79.4±10.8                                   76.5±10.6                78.2±10.8        0.007
  Waist circumference (cm)            99.5±9.0[\*](#t1f2){ref-type="table-fn"},[†](#t1f2){ref-type="table-fn"}    95.3±9.1                                    94.7±8.7                 96.1±9.0         \<0.001
  Visceral adipose tissue (cm^2^)     171.8±52.5                                                                  186.3±56.2                                  180.2±60.6               179.3±57.7       0.322
  Body mass index (kg/m^2^)           29.8±3.9[\*](#t1f2){ref-type="table-fn"},[†](#t1f2){ref-type="table-fn"}    28.3±3.5[‡](#t1f2){ref-type="table-fn"}     26.7±3.1                 27.8±3.6         \<0.001
  Appendicular skeletal muscle (kg)   22.8±4.1[\*](#t1f2){ref-type="table-fn"},[†](#t1f2){ref-type="table-fn"}    20.1±4.9[‡](#t1f2){ref-type="table-fn"}     18.2±4.5                 19.8±4.9         \<0.001
  ASM/body weight (%)                 26.9±2.6[†](#t1f2){ref-type="table-fn"}                                     26.1±3.4                                    25.9±3.1                 26.2±3.1         0.044
  Fasting glucose (mg/dL)             108.0±38.5                                                                  103.9±20.6                                  106.5±22.8               106.3±27.4       0.661
  Total cholesterol (mg/dL)           05.3±37.0[†](#t1f2){ref-type="table-fn"}                                    199.8±42.0                                  190.8±35.4               196.5±37.7       0.013
  Triglycerides (mg/dL)               50.0±59.2[†](#t1f2){ref-type="table-fn"}                                    132.5±67.0                                  116.1±58.7               128.6±62.2       \<0.001
  HDL-cholesterol (mg/dL)             46.2±7.4[†](#t1f2){ref-type="table-fn"}                                     47.4±8.8[‡](#t1f2){ref-type="table-fn"}     50.4±11.0                48.7±9.9         0.004
  LDL-cholesterol (mg/dL)             37.3±34.7[†](#t1f2){ref-type="table-fn"}                                    130.9±36.0[‡](#t1f2){ref-type="table-fn"}   120.9±30.7               127.4±33.6       0.001
  Alanine aminotransferase (IU/mL)    45.3±28.5[\*](#t1f2){ref-type="table-fn"},[†](#t1f2){ref-type="table-fn"}   34.8±20.7                                   31.7±20.4                35.9±23.5        \<0.001
  Uric acid (mg/dL)                   7.1±1.5[\*](#t1f2){ref-type="table-fn"},[†](#t1f2){ref-type="table-fn"}     6.3±1.4[‡](#t1f2){ref-type="table-fn"}      5.7±1.6                  6.2±1.6          \<0.001
  hs-CRP (mg/dL)                      0.2±0.4                                                                     0.1±0.2                                     0.2±0.4                  0.2±0.3          0.586

Values are presented as mean± standard deviation or number (%). One-way analysis of variance with post-hoc least significant difference for continuous variables. Chi-square test for categorical variable.

^\*^*P*\<0.05 between T1 and T2; ^†^*P*\<0.05 between T1 and T3; ^‡^*P*\<0.05 between T2 and T3.

T1, 1st tertile; T2, 2nd tertile; T3, 3rd tertile; ASM, appendicular skeletal muscle; HDL, high-density lipoprotein; LDL, low-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein.
